AUPHAurinia Pharmaceuticals Inc.
Pharmaceutical Preparations
- Revenue
- $283M
- 20% YoY
- Operating margin
- 37.1%
- 1959% YoY
- EBITDA
- $124M
- 743% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired47% of net incomeCash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowClear72% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $46M | $134M | $176M | $235M | $283M | 20% |
| Operating income | −$181M | −$111M | −$92M | −$5M | $105M | 2338% |
| Net income | −$181M | −$108M | −$78M | $6M | $287M | 4852% |
| Operating cash flow | −$158M | −$80M | −$33M | $44M | $136M | 206% |
| Stock-based comp | $31M | $32M | $45M | $32M | $15M | 54% |
| Buybacks | — | $0 | $0 | $40M | $98M | 144% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $190K · 1
- Net
- −$190K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $6M | $18M | 115 | 84 |
| FY2024 | $6M | $8M | 65 | 63 |
| FY2023 | $11M | $15M | 65 | 69 |
| FY2022 | $9M | −$9M | 31 | 70 |
| FY2021 | $1M | $16M | 165 | 92 |